Lipoarabinomannan (LAM) Enzyme-Linked Immunosorbent Assay (ELISA) in Diagnostics of Childhood Tuberculosis (TB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00512330|
Recruitment Status : Unknown
Verified August 2008 by University Hospital, Bonn.
Recruitment status was: Recruiting
First Posted : August 7, 2007
Last Update Posted : August 6, 2008
In children, it remains quite difficult even in developed countries, to prove a diagnosis of Tuberculosis (TB). New means for diagnosis of this disease are currently being researched. One candidate test is Lipoarabinomannan ELISA from Urine, which has shown good sensitivity of up to 80% in adults.
Our study aims to evaluate this test in the diagnosis of children with TB.
|Condition or disease|
Among candidate new diagnostics for TB, a test for mycobacterial Lipoarabinomannan (LAM) excretion in urine has shown promising results in one Tanzanian study: The sensitivity for detecting TB culture-positive patients was 80.3%. Of 103 healthy volunteers, only one gave a false positive result (Boehme, 2005).
Until now, there are only data concerning this test for diagnosis of adult disease. For evaluation of routine use in children in countries like Malawi, we are starting a prospective study. Children 0-14 years of age with suspected TB will be investigated using TB culture as the gold standard. In sputum samples, microscopy will be done. Simultaneously, LAM Elisa from the patient´s urine will be done.
|Study Type :||Observational|
|Estimated Enrollment :||250 participants|
|Official Title:||Evaluation of Urine Lipoarabinomannan ELISA In Diagnostics of Childhood Tuberculosis|
|Study Start Date :||August 2007|
|Estimated Study Completion Date :||August 2008|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00512330
|Contact: Norbert Heinrich, MD||0049 179 email@example.com|
|Contact: John Chimphamba, Clinical Officer||00265 9394287|
|Our Lady of Mount Carmel Hospital||Recruiting|
|Kapiri/Mchinji, Mchinji, Malawi|
|Principal Investigator: John Chimphamba, Clinical Officer|
|Study Chair:||Norbert Heinrich, MD||University of Bonn|
|Principal Investigator:||John Chimphamba, Clinical Officer||Our Lady of Mount Carmel Hospital, Kapiri|
|Study Chair:||Andreas Mueller, PD Dr med.||University of Bonn|